These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 35406564)
1. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. Cattrini C; Caffo O; De Giorgi U; Mennitto A; Gennari A; Olmos D; Castro E Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406564 [TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China. Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046 [TBL] [Abstract][Full Text] [Related]
3. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354 [TBL] [Abstract][Full Text] [Related]
4. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506 [TBL] [Abstract][Full Text] [Related]
5. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison. Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656 [TBL] [Abstract][Full Text] [Related]
6. Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide. Fujmoto S; Fujita K; Nishimoto M; Hamaguchi M; Kuwahara K; Hashimoto M; Adomi S; Minami T; Nozawa M; Yoshimura K; Uemura H Cancer Med; 2023 Feb; 12(3):3176-3179. PubMed ID: 36043427 [TBL] [Abstract][Full Text] [Related]
8. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ? Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646 [TBL] [Abstract][Full Text] [Related]
10. Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. Henriquez I; Spratt D; Gómez-Iturriaga A; Abuchaibe O; Couñago F World J Clin Oncol; 2021 Jan; 12(1):6-12. PubMed ID: 33552935 [TBL] [Abstract][Full Text] [Related]
11. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives. Berruti A; Bracarda S; Caffo O; Cortesi E; D'Angelillo R; Del Re M; Facchini G; Pappagallo G; Procopio G; Sabbatini R; Santini D Cancer Treat Rev; 2023 Apr; 115():102525. PubMed ID: 36822009 [TBL] [Abstract][Full Text] [Related]
12. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer. Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086 [TBL] [Abstract][Full Text] [Related]
13. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis. Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752 [TBL] [Abstract][Full Text] [Related]
15. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128 [TBL] [Abstract][Full Text] [Related]
16. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096 [TBL] [Abstract][Full Text] [Related]
17. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis. Zhang X; Zhang G; Wang J; Bi J Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of nonmetastatic CRPC : Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis]. Hadaschik B; Hellmis E Urologe A; 2021 Jun; 60(6):753-759. PubMed ID: 33575824 [TBL] [Abstract][Full Text] [Related]
20. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Saad F; Bögemann M; Suzuki K; Shore N Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):323-334. PubMed ID: 33558665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]